{'fraction_non_alphanumeric': 0.01826923076923077, 'fraction_numerical': 0.0125, 'mean_word_length': 6.382978723404255, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Antitumour effects of tilorone hydrochloride on the in vivo growth of chemically induced and spontaneously arising rat tumours.

Inhibition of subcutaneous tumour growth, following treatment with tilorone hydrochloride, was observed with two transplantable methylcholanthrene-induced rat sarcomas (Mc7, Mc4), but similar drug treatment was ineffective against two rat hepatomas induced by dimethylaminoazobenzene (D23, D30). Successful therapy of sarcoma Mc7 and Mc4 subcutaneous growth was not accompanied by the development of specific antitumour immunity, although with hepatoma D30, which grew out following tilorone hydrochloride treatment, specific immunity was demonstrated, indicating that drug treatment does not prevent the initiation of an antitumour response during progressive tumour development. Under defined experimental conditions tilorone hydrochloride also prevented pulmonary metastases from a subcutaneous tumour graft of epithelioma SP1 and mammary carcinoma SP22, as measured by an increased survival or treated rats.